This kidney cancer slide show features images of chromophobe, papillary, and clear-cell renal cell carcinomas; as well as sarcomatoid, transitional cell, and small-cell carcinomas of the kidney.
EU’s CHMP Has Positive Opinion for Subcutaneous Nivolumab in Solid Tumors
Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.
Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.
AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC
An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.
Improving NSCLC Surgery Recovery After Climate Disaster Exposure
The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
Solnerstotug Shows Promising Preliminary Data in PD-L1 Resistant Tumors
No dose-limiting toxicities were seen with solnerstotug in patients with PD-L1–resistant tumors, and most adverse effects were grades 1/2 in severity.
HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis
Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.